AWAndrew Wilson

Andrew Wilson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrew Wilson has a total of 254 co-authors. Here are the top co-authors by number of shared publications:

  • Emily Saurman

    Faculty of Medicine and Health, School of Rural Health (Dubbo/Orange) and Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia

    5 shared publications
  • Shannon Nott

    Western NSW Local Health District Dubbo NSW

    5 shared publications
  • Ahmed Hazazi

    Department of Public Health, College of Health Sciences, Saudi Electronic University, Riyadh 13316, Saudi Arabia

    4 shared publications
  • Anna E Thompson

    School of Rural Health University of Sydney Orange NSW

    4 shared publications
  • Tim Shaw

    University of Sydney Sydney NSW

    4 shared publications
  • Amanda Rush

    Leeder Centre for Health Policy, Economics & Data, Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia

    3 shared publications

Latest Publications

  • Open Access

    Health equity in telehealth: applying a nine-dimension equity evaluation framework to two Australian programmes

    by Siyu Wang, Amy Von Huben, Anagha Killedar, Georgia Wingfield, Miranda Shaw, Sarah Norris, Andrew Wilson

  • Open Access

    Perceptions and Self‑Reported Practices of Hospital Pharmacists Regarding Quality Use of Medicines (QUM) in Saudi Arabia

    by Fahad Aldhafeeri, Andrew Wilson, Shaun Larkin

    Introduction: Quality Use of Medicines (QUM) is essential to improving patient safety and care outcomes. This study evaluated the attitudes, perceptions and self‑reported engagement of pharmacists in QUM practices within Saudi Arabia (SA). Methods: A cross-sectional survey was administered to hospital-based pharmacists in Ministry of Health (MOH) hospitals across SA to evaluate four QUM-related aspects: Perception and Attitudes toward QUM, Medication Review, Patient Education and Adherence, and Medication Dosage and Monitoring. Responses were rated on a 5-point scale, and data were analyzed using SPSS version 29. Results: Of 360 surveys, 318 were completed (response rate: 88%). Overall, pharmacists reported high mean scores, indicating favorable attitudes toward QUM concepts and a high perceived importance of QUM‑related activities (mean scores >4 across all domains). The highest mean score was for Perception and Attitudes toward QUM (4.63), while Medication Review had the lowest (4.24). Female pharmacists had higher mean scores across all categories, and younger pharmacists (21–30 years) also had higher scores, particularly in Patient Education and Adherence; however, these subgroup differences were not statistically significant after Bonferroni correction. Conclusion: Pharmacists in this study hold positive perception and attitudes toward QUM principles. However, the study identified gender- and age-related differences, as well as discrepancies between perception and practice, particularly in medication reviews. Thus, there is a need for targeted, tailored training and educational programs to enhance QUM practices among pharmacists in SA.

  • Open Access

    Pharmaceutical registration, essential medicines, and registration depth in Sri Lanka: a longitudinal analysis, 1991–2025

    by Manori Jayasinghe, Amanda Rush, Andrew Wilson

    Access to essential medicines in low- and middle-income countries (LMICs) is influenced by pricing, procurement, and prescribing practices (Hogerzeil et al., 1993; Laing et al., 2003; Management Sc...

  • Open Access

    Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025

    by Michael O. Falster, Juliana de Oliveira Costa, Tamara Y. Milder, Joanne Carson, Cade Shadbolt, Brendon L. Neuen, Clare Arnott, Andrew Wilson, Min Jun, Nicole Pratt, et al.

    Aims: GLP‐1 medicines provide substantial cardio‐renal benefits for type 2 diabetes (T2D) and are increasingly used for weight loss. Most high‐income countries subsidize access for T2D with restrictions; use outside of these restrictions occurs through private prescriptions. Despite strong consumer demand, the extent of private access to GLP‐1 medicines remains poorly quantified. Methods: We used national pharmaceutical sales data to quantify population use of GLP‐1 medicines listed for T2D in Australia, May 2020–April 2025. We used Pharmaceutical Benefits Scheme (PBS) dispensing claims to measure subsidized access; we estimated private access as the difference between sales and PBS dispensings. We measured GLP‐1 medicine use as number of units sold/dispensed and defined daily dose (DDD)/1000 population/day. Results: Since May 2020, total sales of GLP‐1 medicines indicated for T2D increased almost 10‐fold. Most growth was in private access, driven by semaglutide and rapid uptake of tirzepatide. Supply dropped by 79% during periods of global shortage and primarily accessed through subsidized care. In the year May 2024–April 2025, the majority of GLP‐1 medicines used were semaglutide (63.3%) and tirzepatide (30.7%). Half (47.8%) were accessed privately (26.9% of semaglutide; all tirzepatide). In this year, we estimate approximately 483 000–502 000 people accessed GLP‐1 medicines each month, with 180 000–240 000 people accessing privately. Conclusions: Use of GLP‐1 medicines indicated for T2D has increased dramatically, accessed by approximately half a million Australians each month, almost half of which is private. Our findings highlight demands outside of subsided care, equity concerns for access and pressures for health systems in meeting this demand.


  • Open Access

    The Australian MotherSafe enhanced service for nausea and vomiting in pregnancy and hyperemesis gravidarum: a mixed methods study

    by Pippy Walker, Alexis Turner, Sarah Pont, Penelope Fotheringham, Delwyn Cupitt, Andrew Wilson, Debra Kennedy, Amanda Rush

    Background: Nausea and vomiting in pregnancy (NVP) and hyperemesis gravidarum (HG) can have significant physical, psychological and economic impacts on affected women and their families. With the onset of severe symptoms usually occurring in the first trimester and women in Australia typically not engaging in regular antenatal care until beyond this period, there is a gap in access to suitable models of care. In 2023, the MotherSafe teratogen information service introduced an enhanced NVG/HG service that provides medication advice for both over the counter and prescribed medications and psychological support in line with NVP/HG clinical guidelines introduced at a similar time. The aim of this study is to describe service use, patient symptoms and acceptability of the MotherSafe enhanced service for women with NVP and HG in New South Wales (NSW) Australia. Methods: This convergent parallel mixed methods study involved women and family members who contacted the MotherSafe enhanced NVP/HG telephone counselling service from inception (April 2023) to June 2024. Where available, routinely collected service data was analysed to understand service use and changes in NVP symptoms (PUQE-24 score) between the initial and first follow up MotherSafe counselling call ( n = 389). To understand acceptability of the service, semi-structured interviews were conducted with women that had recently accessed the service ( n = 11). Results: During the first 15 months of the enhanced NVP/HG service operation, 1194 initial and 534 follow up MotherSafe counselling calls provided NVP/HG information and advice. Changes in NVP symptoms measured by PUQE-24 scores between initial and follow up call were favourable for women where this data was available ( n = 389, mean score reduction 2.26, p <  0.001), and interview participants reported overall positive experiences that met their needs. Conclusions: The service has the potential to address a health service gap for women with NVP/HG. Further research to more rigorously evaluate change in NVP symptoms following MotherSafe counselling and advice is needed to confirm the effectiveness of the service. Service call numbers and feedback from women suggest that more widespread promotion of the service would support increased reach.


  • Open Access

    Using Social Media for Public Health Communication to Young People: A Qualitative Study to Inform Emergency Preparedness

    by Melody Taba, Julie Ayre, Kirsten McCaffery, Caitlin Blanch, Julie Leask, Andrew Wilson, Carissa Bonner

    The COVID-19 pandemic highlighted the role of social media for official health communication, especially for young people who rarely engage with other public health agency channels. This study explored the social media health communication experiences of health communicators and young people, during and outside the COVID-19 emergency. Semi-structured interviews were conducted with professional health communicators responsible for social media communication of Australian government health departments and young people aged 18-24 years (n = 21). Interviews were analyzed thematically using Framework Analysis. The results revealed health communicators faced challenges in their work, including organizational barriers and misinformation. Whilst the COVID-19 pandemic amplified these challenges, it also brought opportunities like innovation, streamlined approval systems and increased followership. Health communicators targeted young people by using channels popular with the age group and using trendy and engaging formats. Young people found these communications straightforward but not consistently engaging or humorous and recommended involving young people in future messaging to increase appeal. These findings highlight the need for further improvements in social media health communication to youth. Health communicators require increased support and mechanisms allowing innovation in future pandemics.


  • Open Access

    The GLP-1 RA boom: Trends in publicly subsidised and private access in Australia, 2020-2025

    by Michael O Falster, Juliana de Oliveira Costa, Tamara Milder, Joanne M Carson, Cade Shadbolt, Brendon L Neuen, Clare Arnott, Andrew Wilson, Min Jun, Nicole Pratt, et al.

    Objectives: To quantify population-level trends in publicly subsidised and private access of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in Australia. Design: Longitudinal descriptive study using routinely collected data. Setting: National pharmaceutical sales and Pharmaceutical Benefits Scheme (PBS) dispensing claims for GLP-1 RA listed for type 2 diabetes (T2D), May 2020-April 2025. Main outcome measures: We measured GLP-1 RA use according to the total number of units sold/dispensed and defined daily dose (DDD)/1000 population/day. We used sales data to quantify total population use, and PBS dispensings to quantify subsidised access. We estimated private access as the difference between total sales and PBS dispensings. Results: Since May 2020, total sales of GLP-1 RA in Australia increased almost 10-fold, reaching approximately half a million units sold each month in 2024/25, despite significant disruptions to access during shortages. Most growth was in private access, driven initially by semaglutide then rapid uptake of tirzepatide following its market approval. In the year May 2024-April 2025, over 6 million units of GLP-1 RA were sold, predominantly semaglutide (63.3%) and tirzepatide (30.7%); 47.8% of all GLP-1 RA were accessed via the private market, including 26.9% of semaglutide and all tirzepatide. In this period, GLP-1 RA use was estimated to cover 18 out of every 1000 Australians at a standard daily maintenance dose, with 6 out of every 1000 accessing these medicines privately. Conclusions: Australian sales of GLP-1 RAs increased dramatically over the past five years. Half of GLP-1 RA in 2024/25 were accessed in the private market, with an estimated 180,018 to 239,724 Australians accessing GLP-1 RAs privately each month. Our findings underscore the substantial pressures on health systems in meeting the growing demand for these medicines, including rapidly shifting markets, significant demands outside of subsided care, and the need to ensure equitable access and outcomes of use. Summary box: What is already known on the topic: Novel GLP-1 RA medicines have significant cardio-renal benefits, including weight loss for people with type 2 diabetes and obesity. There is strong consumer demand for health systems to subsidise these treatments for obesity, yet subsidised access in high-income countries has generally been limited to people with type 2 diabetes. The extent of private market use is largely unknown. What this study adds: Almost half of GLP-1 RA medicines indicated for type 2 diabetes in Australia are accessed on the private market, most likely for weight loss. There were rapidly shifting trends within subsidised and private markets, with disruptions from global shortages and listing of new medicines. Our findings quantify the potential scope of expanding indications and highlight health system challenges for managing equitable use outside of subsidised healthcare.


  • Open Access

    A scoping review of models of care and services for nausea and vomiting in pregnancy and hyperemesis gravidarum

    by Pippy Walker, Alexis Turner, Swathi Sridharan, Xinrui Dong, Carmen Huckel Schneider, Andrew Wilson, Amanda Rush

    Background: Nausea and vomiting in pregnancy and hyperemesis gravidarum have significant physical and psychological impacts on pregnant women. Women are often unable to participate in everyday care and work activities, potentially affecting individual wellbeing and ability to contribute to the economy. Research priorities for hyperemesis gravidarum have been established, however little is known about the current landscape of literature on the health and social care provided to affected women. To inform decision makers on effective models of care and identify remaining evidence gaps, this scoping review aimed to map existing literature that evaluated health and social care delivery arrangements for pregnant women with nausea and vomiting and hyperemesis gravidarum. Methods: Seven databases (Medline, EMBASE, CINAHL, PsycInfo, Maternity and Infant Care, Cochrane Library and Scopus) were searched in August 2023 and again in March 2024 to identify evaluations of health care delivery arrangements for nausea and vomiting in pregnancy and hyperemesis gravidarum. Database searches were supplemented by a Google search for additional peer-reviewed and grey literature. Data from included publications were extracted and synthesised to report on models of care identified, countries, study designs, outcome measures and key findings. Results: Seventy-two records describing 60 separate models of care were identified. Models of care were grouped into hospital settings (n = 34 records), digital health (n = 19 records), group-based care (n = 11 records), and primary care (n = 8 records). Literature in the hospital setting addressed outpatient management (n = 15 records), inpatient management (n = 5 records), comparisons of outpatient and inpatient management (n = 10 records), in-home care (n = 3 records) and emergency departments (n = 1 record). Digital health care evaluations included telephone and web-based support (n = 14 records) and mobile phone applications (n = 5 records). Conclusions: This scoping review has identified the need for further research on approaches to care provision for nausea and vomiting in pregnancy and hyperemesis gravidarum. Whilst some positive findings on patient outcomes, patient experiences and reduced hospital stays resulting from outpatient hospital management pathways were reported, much of this research was observational and limited to UK settings. Other research gaps identified pertained to the effectiveness of primary care, social support and in-home care services, including economic evaluations.


  • Open Access

    Stakeholder Attitudes, Experiences and Perceptions of the New South Wales Primary School Mobile Dental Program

    by Kanchan Marcus, Carmen Huckel‐Schneider, Anagha Killedar, Madhan Balasubramanian, Arash Rudman, Woosung Sohn, Prithivi Sivaprakash, Sarah Norris, Graeme Liston, Naomi Wilson, et al.

    Objectives: Tooth decay is a leading cause of total disease burden among Australian children. In 2019, the state government of New South Wales, Australia implemented the Primary School Mobile Dental Program (PSMDP) across five local health districts. Understanding stakeholder satisfaction of the PSMDP is an important measure of quality, to determine appropriateness as relevant to the needs of populations. The aim of the study was to explore parent/caregiver and provider attitudes, experiences, and perceptions of the PSMDP.Methods: This study reports on the qualitative component of a mixed methods study examining parent/caregiver and provider (oral health staff) experiences of the program. Two of the five local health districts were selected for study sampling. Parents/caregivers were recruited using flyers administered via schools and oral health teams. Interviews were conducted between 2022 and 2023. The interviews lasted 20–60 min, were recorded, and transcribed verbatim. A critical realist lens was applied, and thematic analysis was conducted. Data saturation was achieved, and bias was reduced through member checking, researcher reflexivity, and team triangulation of the data.Results: In total, 79 individuals (58 parents/caregivers and 21 providers) were interviewed. Analysis revealed six key themes: (1) oral healthcare access, (2) informed consent, (3) parental attendance, (4) rewarding experiences, (5) operational barriers, and (6) communication clarity. The PSMDP promoted oral healthcare access while some parents/caregivers reported informed consent challenges. Providers cited rewarding experiences but face operational barriers including time constraints. Stakeholders diverged on parental attendance at school dental appointments, and most importantly, parents/caregivers requested follow‐up communication clarity and coordination, particularly in feedback letters.Conclusions: Qualitative findings identified generally positive attitudes and experiences with the PSMDP, and implications have been identified that would support the scale‐up and sustainability of the PSMDP across the state. Study insights could be useful for similar programs, such as extending the attendance time per child, giving greater consideration to parental involvement, and improving communication and follow‐up coordination.

  • Open Access

    Identifying core leadership competencies to success non-communicable disease control and prevention programs: A mixed-methods study

    by Jafar Sadegh Tabrizi, Yegane Partovi, Andrew Wilson, Kamal Gholipour, Mostafa Farahbakhsh, Tohid Jafari Koshki, Ahmad Koosha, Jabreil Sharbafi

    Introduction: Strengthening strong leadership skills is essential for program managers to successfully implement programs for the prevention and control of noncommunicable diseases (NCDs). This study identified leadership competencies for managers of individuals with noncommunicable diseases in Iran. Methods: The study had three steps: a literature review, an expert panel, and a Delphi technique survey. First, the literature was reviewed to compile a list of leadership competencies in the field of primary health care (public health, NCDs). To refine and adapt the original list of leadership competencies, it was provided to the expert panel in two stages. The list of leadership competencies was sent via email to 30 experts over the course of two Delphi rounds. Descriptive statistics were used to analyze the outcomes. Results: Fifteen leadership competencies, comprising multisectoral collaboration, political awareness, evidence-informed decision making, risk and disaster management, planning, innovation, leading and managing change, team building, communication, quality improvement, systematic thinking, management, ethics and professionalism, motivation and inspiration and personality, were identified. Conclusion: The leadership competencies identified in this study can be a helpful tool in evaluating and identifying skills, knowledge, and attitudes with program managers for the prevention and control of NCDs and in designing training programs to strengthen leadership skills.